Alzheimer Disease (Alzheimer's Disease)

25404  relevant articles (925 outcomes, 3138 trials/studies) found for this Disease

Alzheimer's Disease; Senile Dementia; Early Onset Alzheimer Disease; Late Onset Alzheimer Disease; Primary Senile Degenerative Dementia; Presenile Dementia; Alzheimer Disease, Early Onset; Alzheimer Disease, Late Onset; Alzheimer Type Senile Dementia; Alzheimer's Disease, Focal Onset; Dementia, Presenile; Dementia, Primary Senile Degenerative; Focal Onset Alzheimer's Disease; Senile Dementia, Acute Confusional; Alzheimer Dementia, Presenile; Alzheimer Type Dementia; Dementia, Presenile Alzheimer; Dementias, Presenile; Dementias, Senile; Disease, Alzheimer; Disease, Alzheimer's; Presenile Dementias; Senile Dementias; Acute Confusional Senile Dementia; Dementia, Alzheimer Type; Dementia, Senile; Presenile Alzheimer Dementia; Senile Dementia, Alzheimer Type

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Dementia (Dementias)
2.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
3.	Parkinson Disease (Parkinson's Disease)
4.	Neurodegenerative Diseases (Neurodegenerative Disease)
5.	Schizophrenia (Dementia Praecox)
619 Diseases and 6515 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Alzheimer Disease:

1.	Amyloid (Amyloid Fibrils)IBA 07/01/2006 - "Most drug discovery efforts for Alzheimer's disease (AD) have focused on prevention or clearance of beta-amyloid (Abeta) fibrils or oligomers, with far less attention to prevention of tau abnormalities that lead to neurofibrillary tangles (NFTs)" 01/01/2006 - "These results demonstrate that phase-contrast X-ray computed tomography is a highly sensitive imaging technique for analyzing dense-cored amyloid plaques in postmortem samples, and is beneficial in elucidating amyloid pathophysiology in Alzheimer's disease." 10/10/2003 - "Deposition of amyloid in the brain is important in the pathogenesis of Alzheimer's disease (AD), but it remains to be determined if deposition is due to increased production or decreased clearance of fibrillogenic forms of beta-amyloid (Abeta)" 09/01/2002 - "The identification of amyloid deposits in living Alzheimer disease (AD) patients is important for both early diagnosis and for monitoring the efficacy of newly developed anti-amyloid therapies" 05/01/2005 - "As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates of amyloid beta-peptide, approaches allowing the direct, noninvasive visualization of plaque growth in vivo would be beneficial for biomedical research" Get all the results and reference details, order at left...
2.	donepezil (Aricept)FDA Link 01/01/2004 - "Despite a sense of limited efficacy of this drug class among prescribers, number needed-to-treat analyses suggest donepezil is highly effective at reducing the long-term adverse outcomes associated with Alzheimer's disease." 10/01/2000 - "There have been a number of randomised, placebo-controlled trials of donepezil in the treatment of mild-moderate Alzheimer's disease and these report significant benefits for a proportion of patients" 03/01/2000 - "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease" 10/01/2003 - "RESULTS: At week 24, both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer's Disease Assessment Scale-cognitive subscale (mean change from baseline score effect size: donepezil 5 mg/d, -1.90; P=0.001; donepezil 10 mg/d, -2.33; P<0.001)" 08/01/2007 - "RESULTS: After 6 weeks of open-label treatment with donepezil 5 mg/day, mean Alzheimer's Disease Assessment Scale -- cognitive subscale scores (ADAS-cog) improved by approximately two points, while after 12 weeks of open-label treatment (with a majority of patients receiving 10 mg/day), the mean ADAS-cog score was 1 point better than the score at the end of the placebo washout period" Get all the results and reference details, order at left...
3.	Cholinesterase Inhibitors (Anticholinesterases)IBA 04/01/2003 - "The most important therapeutic effect of cholinesterase inhibitors (ChEI) on approximately 50% of Alzheimer's disease (AD) patients is to stabilize cognitive function at a steady level during a 1-year period of treatment as compared to placebo" 01/01/2002 - "Cholinesterase inhibitors have produced the best evidence of clinical efficacy for treating patients with Alzheimer's disease (AD)" 08/01/2006 - "PURPOSE: Cholinesterase Inhibitors (ChEIs) have proven efficacy in outpatients with mild to moderate Alzheimer's Disease (AD)" 02/01/2001 - "Despite the proven efficacy of acetylcholinesterase inhibitors in Alzheimer's disease, there is a need for new and more effective treatments" 02/01/1997 - "Although some promising results have been achieved by acetylcholinesterase inhibitors, an effective therapeutic intervention in Alzheimer's disease still remains an important goal" Get all the results and reference details, order at left...
4.	Tacrine (Cognex)FDA Link 02/01/1998 - "CSF concentrations ranged from not detectable to 15.92 ng/mL. The authors support that penetration of tacrine into CSF is highly variable in patients with Alzheimer's disease and that disparity in tacrine concentrations at the site of action may be one reason for conflicting results from studies of the efficacy of tacrine in Alzheimer's disease." 10/29/1992 - "Of 632 eligible patients with probable Alzheimer's disease, 215 improved while receiving tacrine during a preliminary crossover phase to determine responsiveness and the best dose" 11/01/1999 - "OBJECTIVES: By reviewing the key methodological features (sample size, duration, statistical and clinical significance) of clinical trials examining the efficacy of tacrine in the treatment of Alzheimer's disease (AD), we assessed their ability to detect clinically important changes in cognition" 10/18/1988 - "Long-term administration of 9-amino-1,2,3,4-tetrahydroacridine (THA) has been reported to produce marked clinical improvement in patients suffering from Alzheimer's disease" 10/29/1992 - "In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients." Get all the results and reference details, order at left...
5.	rivastigmine (Exelon)FDA LinkGeneric 04/01/2008 - "This study shows that long-term treatment with rivastigmine, at dosages approved for therapeutic use in Alzheimer's disease, produces significant improvement in all behavioral symptoms in 2 forms of VaD, MID and sVaD, except delusions" 12/01/2002 - "Rivastigmine has demonstrated significant benefits in patients with mild to moderate Alzheimer's disease (AD)" 01/01/2000 - "REVIEWER'S CONCLUSIONS: Rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease" 01/01/2003 - "The results of recent clinical trials with rivastigmine show that in the approved indication of mild to moderate Alzheimer's disease (AD), the drug is effective in the long term" 01/01/2003 - "Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions." Get all the results and reference details, order at left...
6.	Memantine (Namenda)FDA Link 03/01/2008 - "CONCLUSIONS: This post hoc analysis provides important evidence from placebo-controlled trials that memantine may be a safe and effective treatment in Alzheimer's disease patients with agitation/aggression or psychosis, who are otherwise prone to rapid progression" 06/01/2006 - "Phase 3 (final) clinical trials have shown that memantine is effective in treating moderate-to-severe Alzheimer's disease while being well tolerated" 10/01/2005 - "Memantine was effective and safe in several clinical studies, particularly in Alzheimer's disease" 05/01/2006 - "Memantine is in a new class of drugs useful in the treatment of Alzheimer's disease" 01/01/2003 - "Memantine has been demonstrated to be safe and effective in the symptomatic treatment of Alzheimer's disease (AD)" Get all the results and reference details, order at left...
7.	Galantamine (Galanthamine)IBA 04/11/2006 - "INTERPRETATION: Clinicians, but not patients and caregivers, observed a significantly greater improvement in goal attainment among patients with mild to moderate Alzheimer's disease who were taking galantamine than among those who were taking placebo." 01/01/2001 - "The alkaloid (-)-galanthamine is known to produce significant improvement of cognitive performances in patients with the Alzheimer's disease" 12/09/2000 - "RESULTS: At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's disease assessment scale than patients in the placebo group (mean treatment effect 2.9 points for lower dose and 3.1 for higher dose, intention to treat analysis, P<0.001 for both doses)" 09/01/2006 - "Galantamine was effective in mild-to-moderate Alzheimer disease." 11/01/2001 - "Galantamine is also effective in the treatment of mild to moderate Alzheimer disease symptoms" Get all the results and reference details, order at left...
8.	AcetylcholinesteraseIBA 01/01/2006 - "As a consequence of their capability to simultaneously interact with two binding sites of the same biological target (the enzyme acetylcholinesterase in most cases), to expand their interaction in the main binding site of the target molecule, or to interact with two different biological targets of interest in the pathogenesis of the disease, these dimeric or hybrid compounds exhibit an improved pharmacological profile including high affinity interactions, additional non conventional actions or complementary actions, what makes them potential drug candidates for the treatment of Alzheimer's disease" 10/08/1998 - "Acetylcholinesterase (AChE) inhibitors are one of the most actively investigated classes of compounds in the search for an effective treatment of Alzheimer's disease" 03/15/2008 - "Currently, the only clinically effective treatment for Alzheimer's disease (AD) is the use of acetylcholinesterase (AChE) inhibitors" 12/01/2005 - "OBJECTIVE: To study the efficacy of cognitive rehabilitation combined with acetylcholinesterase inhibitor (AChE-I) treatment in patients with mild Alzheimer's disease and their relatives" 03/01/2007 - "The efficacy of the inhibitors of acetylcholinesterase in Alzheimer's Disease (AD) is moderated and some patients do not respond to these treatments" Get all the results and reference details, order at left...
9.	Cholinesterases (Cholinesterase)IBA 04/01/1994 - "Taken together with our earlier work, which has failed to demonstrate mnemonic deficits following lesions to the magnocellular neurons of the nucleus basalis of Meynert, these results suggest that the most consistent deficit produced following lesions of the BF-cortical cholinergic system is attentional dysfunction Analogous deficits in visual attention are also seen in patients with Alzheimer's disease, which can also be improved by anti-cholinesterase treatment." 03/01/2004 - "BACKGROUND: Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease" 04/01/1997 - "The association of anti-inflammatory and cholinesterase inhibiting activities within the same compound may prove useful for the treatment of Alzheimer's disease." 07/01/2004 - "OBJECTIVE: The authors evaluated the efficacy of a new cognitive rehabilitation program on memory and functional performance of mildly impaired Alzheimer disease (AD) patients receiving a cholinesterase inhibitor" 12/28/2004 - "OBJECTIVE: To evaluate the efficacy of a cognitive-motor program in patients with early Alzheimer disease (AD) who are treated with a cholinesterase inhibitor (ChEI)" Get all the results and reference details, order at left...
10.	Estrogens (Estrogen)FDA Link 03/04/1998 - "Four trials of estrogen therapy in women with Alzheimer disease have been conducted and have had primarily positive results, but most have been small, of short duration, non-randomized, and uncontrolled" 08/01/1997 - "A growing body of evidence supports the hypothesis that estrogens may be beneficial in Alzheimer's disease and other neurodegenerative processes" 07/01/2002 - "CONCLUSIONS: Clinical trials indicate that oral conjugated equine estrogen is not an effective treatment for Alzheimer disease in postmenopausal women." 01/01/2005 - "Postmenopausal therapy with estrogens may be effective in protection against Alzheimer disease." 12/01/2002 - "Post-menopausal estrogen therapy is associated with a decreased incidence of Alzheimer disease and in vitro models have shown that 17beta-estradiol is effective in lowering amyloidogenic processing" Get all the results and reference details, order at left...
2842 Drugs and Important Bio-Agents and 24545 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Activities of Daily Living (ADL) 01/01/2004 - "It has been shown to provide significant benefits in cognition, global function and activities of daily living in patients with mild-to-moderate Alzheimer's disease" 01/01/2008 - "With repeated weekly dosing, sustained improvement at 1 month is documented, with a more than 10-point improvement in the patient's abilities to perform activities of daily living as measured by a standardized instrument, the Alzheimer's Disease Cooperative Study-Activities of Daily Living inventory" 07/01/2000 - "Using the Clinician's Global Rating of Change as a gold standard for change, differences between Bristol Activities of Daily Living Scale scores before and after medication were compared with change in Mini-Mental State Examination, Alzheimer's Disease Assessment Scale - Cognitive and the Nurses Observation Scale for Geriatric Patients, in 61 older adults receiving anticholinesterase medication for Alzheimer's disease" 05/01/1999 - "It benefited the cognitive decline, psychiatric and behavioral disturbances, impaired ability to perform instrumental and basic activities of daily living, and global state of patients diagnosed with mild-to-moderate Alzheimer's disease." 08/01/1998 - "Those drugs currently available, and those in development, may offer effective treatment for some of the core symptoms of Alzheimer's disease, slowing the rate of cognitive decline and preserving competence in activities of daily living for longer" Get all the results and reference details, order at left...
2.	Estrogen Replacement Therapy 06/01/2001 - "Estrogen replacement therapy in menopausal women has been suggested to be beneficial in preventing the progression of cognitive impairment in Alzheimer disease" 05/01/2000 - "It has been shown that estrogen replacement in menopausal women is effective in slowing down the progression of cognitive impairment in Alzheimer's disease" 02/23/2000 - "CONTEXT: Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women" 01/01/1998 - "Epidemiologic studies suggest protective effects against Alzheimer's disease from postmenopausal estrogen replacement and nonsteroidal anti-inflammatory drugs" 10/01/1998 - "Collectively, these data demonstrate the ability for estrogen replacement to attenuate specific pharmacologically induced impairments in learning and retention and provide additional clues as to potential mechanisms by which estrogen replacement may help to reduce cognitive deficits associated with aging and Alzheimer's disease in postmenopausal women." Get all the results and reference details, order at left...
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement) 06/01/2004 - "There is currently intense controversy regarding the use of hormone replacement therapy (HRT) in postmenopausal women, in relation to its therapeutic efficacy in Alzheimer's disease (AD)" 06/01/2002 - "There is only limited evidence that hormone replacement therapy is effective in women already suffering from Alzheimer's disease" 03/01/2003 - "It is biologically plausible that hormone replacement therapy (HRT) would be protective against cognitive decline and Alzheimer's disease (AD)" 02/01/2005 - "The relationship between menopause and cognitive decline has been the subject of intense research since a number of studies have shown that hormone replacement therapy could reduce the risk of developing Alzheimer's disease in women" 01/01/2004 - "Despite promising epidemiological studies that showed a decreased incidence of Alzheimer disease (AD) in women who used hormone replacement therapy (HRT), the results of the recently released Women's Health Initiative Memory Study has dampened any enthusiasm for the use of HRT in women to prevent or delay the onset of AD" Get all the results and reference details, order at left...
4.	Therapeutics 08/01/2006 - "The authors employed a novel approach to identify therapeutics effective in Alzheimer disease (AD)" 08/01/2007 - "Metal-based therapeutics have already provided promising results for the treatment of Alzheimer's disease, and new generations of pharmaceuticals are being developed" 03/01/2005 - "These similarities increase the likelihood that the model will be able to accurately predict the efficacy of Alzheimer's disease (AD) treatments as well as detect therapeutics with limited or no efficacy" 12/01/2007 - "This is supported by preliminary studies showing response to vascular therapeutics and ventriculo-peritoneal shunting in patients with Alzheimer's disease" 10/01/2007 - "Trials and tribulations of evidence-based medicine: the case of Alzheimer disease therapeutics." Get all the results and reference details, order at left...
5.	Immunotherapy 11/01/2006 - "Immunotherapy holds great promise for Alzheimer's disease (AD) and other conformational disorders but certain adverse reactions need to be overcome" 07/01/2008 - "Provided that the ongoing and planned clinical trials address these issues in a timely manner, there is a good chance for Abeta immunotherapy to be one of the first disease-modifying therapies of Alzheimer's disease to be introduced into clinical practice." 07/01/2008 - "More than 10 clinical trials of Abeta immunotherapy are currently underway in patients with Alzheimer's disease (AD)" 05/10/2005 - "CONCLUSION: Although interrupted, this trial provides an indication that Abeta immunotherapy may be useful in Alzheimer disease." 06/01/2008 - "Tissue amyloid plaque immuno-reactive (TAPIR) antibody was better related to the effect of immunotherapy in Alzheimer's disease (AD) than ELISA antibody" Get all the results and reference details, order at left...
139 Therapies and Procedures and 1468 more articles analyzed in the Full Patient-Physician Summary Report, order at left...